ERBB2 and non-small cell lung carcinoma: Pyrotinib combined with apatinib showed encouraging antitumor activity and an acceptable safety profile in metastatic NSCLC patients with heterogeneous HER2 mutations or amplification, indicating that it might be a potential effective strategy for HER2-mutant or HER2-amplified NSCLC.